Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer - Tabular View

Tracking Information
First Received Date ^ICMJE	May 30, 2002
Last Updated Date	January 10, 2008
Start Date ^ICMJE
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00038428 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
Official Title ^ICMJE
Brief Summary	The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.
Detailed Description
Study Phase	Phase II
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Condition ^ICMJE	Ovarian Neoplasms
Intervention ^ICMJE	Drug: TLK286
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	40
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria Histologic diagnosis of ovarian cancer Recurrent or persistent disease following primary therapy Measurable disease Prior treatment with at least one but no more than three prior chemotherapy regimens Resistant or refractory to platinum-based chemotherapy At least 18 years of age Good performance status (ECOG 0 to 1) Adequate liver, renal and bone marrow function Exclusion criteria Pregnant or currently breast feeding Treatment with chemotherapy or immunotherapy within four weeks Prior radiation to the whole pelvis
Gender	Female
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00038428
Responsible Party
Study ID Numbers ^ICMJE	TLK286.2003
Study Sponsor ^ICMJE	Telik
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Telik
Verification Date	February 2007
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP